Location History:
- Bronxville, NY (US) (1985)
- Amherst, NY (US) (1986)
- Durham, NC (US) (1989)
Company Filing History:
3 out of 1,997 
1 out of 5,198 
Years Active: 1985-1989
Title: Michael E Perlman: Innovator in Antineoplastic Agents and Immunoassays
Introduction
Michael E Perlman is a distinguished inventor based in Durham, NC (US). He has made significant contributions to the fields of chemistry and medicine, particularly in the development of novel compounds and methods for cancer treatment and diagnostic assays. With a total of 4 patents, Perlman's work has had a notable impact on both academic and commercial sectors.
Latest Patents
Among his latest patents, Perlman has developed a method involving novel bis(2,2-dimethyl-1-aziridinyl) phosphinic amides for use in inhibiting the replication of tumor cells. This innovative approach utilizes antineoplastic agents that can be administered to tumor cells, showcasing his commitment to advancing cancer therapies. Additionally, he has created a method for enhancing signals in immunoassays through the modulation of chemical catalysis. This method involves the use of an enzyme, a metal ion catalyst, and a blocked modulator, which together facilitate the detection of ligands in fluid samples. The resulting signal change indicates the presence or absence of the target ligand, demonstrating the practical applications of his inventions.
Career Highlights
Throughout his career, Michael E Perlman has worked with reputable organizations, including the State University of New York and Becton Dickinson and Company Limited. His experience in these institutions has allowed him to collaborate with leading experts in his field and contribute to groundbreaking research.
Collaborations
Perlman has collaborated with notable colleagues such as Thomas J Bardos and Joan E MacDiarmid. These partnerships have further enriched his research and innovation efforts, leading to advancements in his areas of expertise.
Conclusion
Michael E Perlman stands out as a prominent inventor whose work in antineoplastic agents and immunoassays continues to influence the scientific community. His innovative patents and collaborations reflect his dedication to improving healthcare through research and development.